Eli Lilly buys three vaccine firms for 4 billion dollars
Eli Lilly will acquire Curevo, LimmaTech Biologics, and Vaccine Co for nearly 4 billion dollars. The move expands its reach into vaccines for shingles and viruses.
Xurve View
Insights:
Xurve View
ELI LILLY & CO will acquire three vaccine developers for up to $4 billion, marking a major expansion into infectious disease prevention. The drugmaker is deploying cash from its obesity franchise to diversify into new therapeutic areas. The deals signal a shift toward long-term revenue stability beyond the current weight-loss boom.
Lilly shares rose 1.6% in premarket trading following the announcement. The Wall Street Journal first reported the acquisitions on Tuesday morning.
